🚀 VC round data is live in beta, check it out!
Janux Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Janux Therapeutics and similar public comparables like OPKO Health, Chabiotech, Jade Biosciences, Sanofi India and more.
Janux Therapeutics Overview
About Janux Therapeutics
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Founded
2017
HQ
Employees
81
Website
Sectors
Financials (LTM)
Market Cap
$884M
Janux Therapeutics Financials
Janux Therapeutics reported last 12-month revenue of $11M and negative EBITDA of ($165M).
In the same LTM period, Janux Therapeutics generated $11M in gross profit, ($165M) in EBITDA losses, and had net loss of ($158M).
Revenue (LTM)
Janux Therapeutics P&L
In the most recent fiscal year, Janux Therapeutics reported revenue of $10M and EBITDA of ($156M).
Janux Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $11M | XXX | $10M | XXX | XXX | XXX |
| Gross Profit | $11M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($165M) | XXX | ($156M) | XXX | XXX | XXX |
| EBITDA Margin | (1518%) | XXX | (1556%) | XXX | XXX | XXX |
| EBIT Margin | (1537%) | XXX | (1577%) | XXX | XXX | XXX |
| Net Profit | ($158M) | XXX | ($114M) | XXX | XXX | XXX |
| Net Margin | (1451%) | XXX | (1136%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Janux Therapeutics Stock Performance
Janux Therapeutics has current market cap of $884M.
Market Cap Evolution
Janux Therapeutics' stock price is $14.53.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $884M | -0.1% | XXX | XXX | XXX | $-1.87 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJanux Therapeutics Valuation Multiples
Janux Therapeutics trades at (5.6x) EV/Revenue multiple, and 0.4x EV/EBITDA.
EV / Revenue (LTM)
Janux Therapeutics Financial Valuation Multiples
As of April 11, 2026, Janux Therapeutics has market cap of $884M.
Equity research analysts estimate Janux Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Janux Therapeutics has a P/E ratio of (5.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $884M | XXX | $884M | XXX | XXX | XXX |
| EV (current) | ($61M) | XXX | ($61M) | XXX | XXX | XXX |
| EV/Revenue | (5.6x) | XXX | (6.1x) | XXX | XXX | XXX |
| EV/EBITDA | 0.4x | XXX | 0.4x | XXX | XXX | XXX |
| EV/EBIT | 0.4x | XXX | 0.4x | XXX | XXX | XXX |
| EV/Gross Profit | (5.6x) | XXX | — | XXX | XXX | XXX |
| P/E | (5.6x) | XXX | (7.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Janux Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Janux Therapeutics Margins & Growth Rates
Janux Therapeutics' revenue in the last 12 month grew by 2%.
Janux Therapeutics' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $2.1M for the same period.
Janux Therapeutics' rule of 40 is (1402%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Janux Therapeutics' rule of X is (1354%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Janux Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Margin | (1518%) | XXX | (1556%) | XXX | XXX | XXX |
| EBITDA Growth | 26% | XXX | 22% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (1402%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (1354%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 399% | XXX | 418% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1230% | XXX | 1259% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1677% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Janux Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| OPKO Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Chabiotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Jade Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| SELLAS Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Janux Therapeutics M&A Activity
Janux Therapeutics acquired XXX companies to date.
Last acquisition by Janux Therapeutics was on XXXXXXXX, XXXXX. Janux Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Janux Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialJanux Therapeutics Investment Activity
Janux Therapeutics invested in XXX companies to date.
Janux Therapeutics made its latest investment on XXXXXXXX, XXXXX. Janux Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Janux Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Janux Therapeutics
| When was Janux Therapeutics founded? | Janux Therapeutics was founded in 2017. |
| Where is Janux Therapeutics headquartered? | Janux Therapeutics is headquartered in United States. |
| How many employees does Janux Therapeutics have? | As of today, Janux Therapeutics has over 81 employees. |
| Who is the CEO of Janux Therapeutics? | Janux Therapeutics' CEO is David Campbell. |
| Is Janux Therapeutics publicly listed? | Yes, Janux Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Janux Therapeutics? | Janux Therapeutics trades under JANX ticker. |
| When did Janux Therapeutics go public? | Janux Therapeutics went public in 2021. |
| Who are competitors of Janux Therapeutics? | Janux Therapeutics main competitors are OPKO Health, Chabiotech, Jade Biosciences, Sanofi India. |
| What is the current market cap of Janux Therapeutics? | Janux Therapeutics' current market cap is $884M. |
| What is the current revenue of Janux Therapeutics? | Janux Therapeutics' last 12 months revenue is $11M. |
| What is the current revenue growth of Janux Therapeutics? | Janux Therapeutics revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Janux Therapeutics? | Current revenue multiple of Janux Therapeutics is (5.6x). |
| Is Janux Therapeutics profitable? | No, Janux Therapeutics is not profitable. |
| What is the current EBITDA of Janux Therapeutics? | Janux Therapeutics has negative EBITDA and is not profitable. |
| What is Janux Therapeutics' EBITDA margin? | Janux Therapeutics' last 12 months EBITDA margin is (1518%). |
| What is the current EV/EBITDA multiple of Janux Therapeutics? | Current EBITDA multiple of Janux Therapeutics is 0.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.